glp 1 discontinuation rates Weight maintenance after of GLP-1 therapies Discontinuation and Reinitiation of Dual-Labeled

Its the classic story of a small farming town becoming a tourist-driving city

In a mouse model of osteoarthritis induced by destabilization of the medial meniscus, glycoursodeoxycholic acid was found to mitigate disease progression, an effect associated with an increase in intestinal L cell numbers (87)

It serves as a natural carrier for fatty acids, hormones, and drugs through multiple binding sites and undergoes neonatal Fc receptor-mediated recycling, which protects it from renal clearance and lysosomal degradation

Sep 2024 - Global pharmaceutical company Amneal Pharmaceuticals, Inc., and clinical-stage biopharmaceutical company Metsera, Inc., are accelerating next-generation medicines for obesity and metabolic diseases by joining forces with a portfolio of new weight loss medicines on efficient development and large-scale supply worldwide

Another leading hypothesis is that IL-6 induced GLP-1 is a part of a negative-feedback loop to inhibit or restrain inflammatory responses